PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10498841-3	1999	In search of modulators of CFTR, we investigated the effects of the non-sulphonylurea hypoglycaemic agents meglitinide, repaglinide, and mitiglinide (KAD-1229) on CFTR Cl- channels in excised inside-out membrane patches from C127 cells expressing wild-type human CFTR.	mitiglinide	137-148	cystic fibrosis transmembrane conductance regulator	Mus musculus	163-167
10498841-3	1999	In search of modulators of CFTR, we investigated the effects of the non-sulphonylurea hypoglycaemic agents meglitinide, repaglinide, and mitiglinide (KAD-1229) on CFTR Cl- channels in excised inside-out membrane patches from C127 cells expressing wild-type human CFTR.	mitiglinide	137-148	CF transmembrane conductance regulator	Homo sapiens	163-167
10498841-5	1999	When added to the intracellular solution, meglitinide and mitiglinide inhibited CFTR Cl- currents with half-maximal concentrations of 164+/-19 microM and 148+/-36 microM, respectively.	mitiglinide	58-69	CF transmembrane conductance regulator	Homo sapiens	80-84
26011816-4	2016	In the mitiglinide/voglibose group, serum LDL-C levels did not change, while sd-LDL levels and sd-LDL/LDL-C decreased significantly (-8.6% and -7.9%) and LDL-C/apoB increased significantly (5.8%).	mitiglinide	7-18	component of oligomeric golgi complex 2	Homo sapiens	42-47
31884929-4	2020	Over the past half century, these drugs, together with the subsequent non-sulfonylureas (glinides), have been the main oral drugs for insulin secretion.	mitiglinide	89-97	insulin	Homo sapiens	134-141
31884929-7	2020	RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus.	mitiglinide	26-34	insulin	Homo sapiens	70-77
31884929-7	2020	RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus.	mitiglinide	26-34	insulin	Homo sapiens	192-199
31884929-7	2020	RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus.	mitiglinide	26-34	insulin	Homo sapiens	192-199
10498841-12	1999	Analysis of the dwell time distributions of single channels indicated that both meglitinide and mitiglinide greatly decreased the open time of CFTR.	mitiglinide	96-107	CF transmembrane conductance regulator	Homo sapiens	143-147
10498841-15	1999	Inhibition of CFTR by meglitinide and mitiglinide was voltage-dependent: at positive voltages channel blockade was relieved.	mitiglinide	38-49	CF transmembrane conductance regulator	Homo sapiens	14-18
10509738-5	1999	These findings suggest a much higher affinity of glibenclamide than S21403 for the artificial phospholipid bilayer, this coinciding with a higher biological potency, as insulin secretagogue, of the hypoglycemic sulfonylurea as compared to meglitinide analog.	mitiglinide	68-74	insulin	Homo sapiens	169-176
30621663-8	2019	After several therapeutic trials, cessation of exogenous insulin and addition of mitiglinide to liraglutide with voglibose finally attenuated glycemic fluctuations with increased postprandial insulin secretion.	mitiglinide	81-92	insulin	Homo sapiens	192-199
26011816-4	2016	In the mitiglinide/voglibose group, serum LDL-C levels did not change, while sd-LDL levels and sd-LDL/LDL-C decreased significantly (-8.6% and -7.9%) and LDL-C/apoB increased significantly (5.8%).	mitiglinide	7-18	component of oligomeric golgi complex 2	Homo sapiens	102-107
26011816-4	2016	In the mitiglinide/voglibose group, serum LDL-C levels did not change, while sd-LDL levels and sd-LDL/LDL-C decreased significantly (-8.6% and -7.9%) and LDL-C/apoB increased significantly (5.8%).	mitiglinide	7-18	component of oligomeric golgi complex 2	Homo sapiens	102-107
26011816-4	2016	In the mitiglinide/voglibose group, serum LDL-C levels did not change, while sd-LDL levels and sd-LDL/LDL-C decreased significantly (-8.6% and -7.9%) and LDL-C/apoB increased significantly (5.8%).	mitiglinide	7-18	apolipoprotein B	Homo sapiens	160-164
25560470-1	2015	Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels.	mitiglinide	49-60	insulin	Homo sapiens	84-91
26336611-14	2015	Additional therapy to sitagliptin or mitiglinide is clearly required to obtain equivalent glycemic control in patients using a higher dose of insulin.	mitiglinide	37-48	insulin	Homo sapiens	142-149
25810423-0	2015	Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.	mitiglinide	22-33	insulin	Homo sapiens	146-153
25810423-4	2015	Recently, it has been reported that the combination therapy of mitiglinide with a DPP-4 inhibitor could improve glycemic control.	mitiglinide	63-74	dipeptidyl peptidase 4	Homo sapiens	82-87
25810423-10	2015	Hence, we have demonstrated the efficacy and safety of the add-on treatment with mitiglinide in type 2 diabetic patients, receiving the combination therapy of sitagliptin and insulin glargine.	mitiglinide	81-92	insulin	Homo sapiens	175-182
25560470-1	2015	Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels.	mitiglinide	49-60	insulin	Homo sapiens	142-149
24488695-0	2014	Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy.	mitiglinide	21-32	dipeptidyl peptidase 4	Homo sapiens	84-89
25046055-8	2014	CONCLUSION: This study revealed that adding the mitiglinide/voglibose combination to a DPP-4 inhibitor elicited additive improvements in postprandial glycemic/metabolic responses assessed using MTTs at breakfast, lunch and dinner with identical meal compositions.	mitiglinide	48-59	dipeptidyl peptidase 4	Homo sapiens	87-92
24842616-3	2014	A novel series of mitiglinide derivatives (o-FMIT, m-FMIT and p-FMIT; FMITs) were synthesized and their binding affinity for the sulfonylurea receptor 1 (SUR1) of pancreatic islets were evaluated by inhibition studies.	mitiglinide	18-29	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	129-152
24842616-3	2014	A novel series of mitiglinide derivatives (o-FMIT, m-FMIT and p-FMIT; FMITs) were synthesized and their binding affinity for the sulfonylurea receptor 1 (SUR1) of pancreatic islets were evaluated by inhibition studies.	mitiglinide	18-29	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	154-158
24488695-9	2014	Following the addition of mitiglinide to the treatment regimen for 52 weeks, the early postprandial decrease in insulin secretion improved and PPG improved in both the DPP-4 inhibitor CTG and biguanide CTG.	mitiglinide	26-37	dipeptidyl peptidase 4	Homo sapiens	168-173
24488695-3	2014	The aim of this study was to investigate the long-term efficacy and safety of mitiglinide in Japanese type 2 diabetic patients inadequately controlled by dipeptidyl peptidase-4 (DPP-4) inhibitor or biguanide monotherapy.	mitiglinide	78-89	dipeptidyl peptidase 4	Homo sapiens	154-176
23992284-1	2013	INTRODUCTION: Mitiglinide , a rapid-acting insulin secretion-stimulating agent, is approved in Japan for the treatment of type 2 diabetes (T2DM).	mitiglinide	14-25	insulin	Homo sapiens	43-50
24215809-18	2013	CONCLUSIONS: Mitiglinide improved postprandial insulin secretion pattern and thereby suppressed postprandial glucose spike.	mitiglinide	13-24	insulin	Homo sapiens	47-54
21923736-10	2012	The C(SS) for gliclazide, glipizide, mitiglinide and nateglinide lie between IC(50) values for SUR1 and SUR2A/SUR2B, suggesting that these drugs bind selectively to pancreatic receptors.	mitiglinide	37-48	ATP binding cassette subfamily C member 8	Homo sapiens	95-99
23797928-0	2013	Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus.	mitiglinide	11-22	insulin	Homo sapiens	39-46
22994875-8	2012	Mitiglinide and the combination restored early insulin response, whereas the combination provided an insulin-sparing effect compared with mitiglinide alone.	mitiglinide	0-11	insulin	Homo sapiens	47-54
22129626-0	2012	Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM.	mitiglinide	0-11	fibroblast growth factor 21	Homo sapiens	43-70
22129626-8	2012	In nT2DM patients, fasting plasma FGF-21 concentrations were significantly decreased after mitiglinide treatment for 16 weeks (3.21 +- 1.37 vs. 2.79 +- 1.14mug/L, P<0.05), accompanied by significant amelioration of glucose metabolism.	mitiglinide	91-102	fibroblast growth factor 21	Homo sapiens	34-40
22129626-9	2012	Our study showed that mitiglinide treatment decreased plasma FGF-21 levels, and this decrease might be associated with the amelioration of glucose metabolism.	mitiglinide	22-33	fibroblast growth factor 21	Homo sapiens	61-67
20841518-1	2010	OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus.	mitiglinide	81-92	insulin	Homo sapiens	109-116
19506328-8	2009	In type 2 diabetic patients combination therapy with mitiglinide and pioglitazone exerted significant long-term improvements in HbA(1C), FPG, and PPG and was well tolerated.	mitiglinide	53-64	serglycin	Homo sapiens	146-149
19027977-4	2009	The serum cystatin C level was measured in 36 patients (19 in the miglitol group and 17 in the mitiglinide group) undergoing meal tolerance testing.	mitiglinide	95-106	cystatin C	Homo sapiens	10-20
17359941-7	2007	The K(m) values of MGN glucuronidation in recombinant UGT1A3 and UGT2B7 microsomes were close to those in human liver microsomes.	mitiglinide	19-22	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	54-60
17359941-7	2007	The K(m) values of MGN glucuronidation in recombinant UGT1A3 and UGT2B7 microsomes were close to those in human liver microsomes.	mitiglinide	19-22	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	65-71
17359941-8	2007	The formation of MGN glucuronidation by human liver microsomes was effectively inhibited by quercetin (substrate for UGT1A3) and diclofenac (substrate for UGT2B7), respectively.	mitiglinide	17-20	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	117-123
17359941-8	2007	The formation of MGN glucuronidation by human liver microsomes was effectively inhibited by quercetin (substrate for UGT1A3) and diclofenac (substrate for UGT2B7), respectively.	mitiglinide	17-20	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	155-161
17003348-5	2006	However, in the context of beta-cells from sulfonylurea receptor 1 (SUR1) knockout mice, TIRF images showed that only mitiglinide, but not glibenclamide, caused fusion of newcomer insulin granules.	mitiglinide	118-129	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	43-66
17592198-3	2007	Mitiglinide is considered to have little or no impact on the cardioprotective effect of ischemic preconditioning (IP) because of its high selectivity for blocking sulfonylurea receptor1 (SUR1).	mitiglinide	0-11	ATP binding cassette subfamily C member 8	Rattus norvegicus	163-185
17185877-0	2007	Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study.	mitiglinide	45-56	insulin	Homo sapiens	147-154
17003348-5	2006	However, in the context of beta-cells from sulfonylurea receptor 1 (SUR1) knockout mice, TIRF images showed that only mitiglinide, but not glibenclamide, caused fusion of newcomer insulin granules.	mitiglinide	118-129	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	68-72
17003348-6	2006	Compositely, our data indicate that 1) the mechanism by which both sulfonylurea and glinide drugs promote insulin release entails the preferential fusion of newcomer, rather than previously docked, insulin granules, and that 2) mitiglinide can induce insulin release by a mechanism independent of mitiglinide binding to SUR1.	mitiglinide	228-239	ATP binding cassette subfamily C member 8	Rattus norvegicus	320-324
16785606-13	2006	(2) Mitiglinide increased LPL mRNA expression 120 min after its administration, and significantly decreased peripheral TG and chylomicron- TG levels after fat challenge in the 24-wk-old OLETF rats.	mitiglinide	4-15	lipoprotein lipase	Rattus norvegicus	26-29
16543674-1	2006	Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes.	mitiglinide	0-11	insulin	Homo sapiens	43-50
16543674-2	2006	While mitiglinide enhances postprandial requirement of insulin, the efficacy of mitiglinide combined with insulin has yet to be established.	mitiglinide	6-17	insulin	Homo sapiens	55-62
16543674-3	2006	We investigated the efficacy of mitiglinide combined with insulin glargine, the first soluble insulin analog that has a flat and prolonged effect.	mitiglinide	32-43	insulin	Homo sapiens	94-101
15467258-2	2004	Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia.	mitiglinide	0-11	insulin	Homo sapiens	36-43
15467258-2	2004	Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia.	mitiglinide	0-11	insulin	Homo sapiens	146-153
15467258-3	2004	In studies of various cloned K(ATP) channels, mitiglinide shows a higher selectivity for the beta-cell type of SUR1/Kir6.2 than the cardiac and smooth muscle types of K(ATP) channels in comparison with glibenclamide and glimepiride.	mitiglinide	46-57	ATP binding cassette subfamily C member 8	Homo sapiens	111-115
15467258-3	2004	In studies of various cloned K(ATP) channels, mitiglinide shows a higher selectivity for the beta-cell type of SUR1/Kir6.2 than the cardiac and smooth muscle types of K(ATP) channels in comparison with glibenclamide and glimepiride.	mitiglinide	46-57	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	116-122
11264248-2	2001	We have investigated the mechanism of action of the novel anti-diabetic agent mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium (K(ATP)) channel.	mitiglinide	78-89	ATP-binding cassette sub-family C member 8	Xenopus laevis	110-114